Trial
NCT06312020
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Sjogren's Syndrome
Intervention
HZN-1116
Why stopped
The study was terminated by sponsor due to meeting pre-defined criteria for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-08